

Canadian Agency for Drugs and Technologies in Health

Karen Lee, Director Health Economics

February 25, 2019

Tokyo, Japan

CADTH

Disclosure

- Employed by CADTH
- No conflicts to my knowledge
- CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec
- CADTH charges application fees for three of its programs:
 - CADTH Common Drug Review
 - CADTH pan-Canadian Oncology Drug Review
 - CADTH Scientific Advice

Presentation

- Overview of the Canadian health care system
- Use of health technology assessment (HTA) in Canada
- Role of CADTH

Health Care Provision in Canada

- Health care in Canada determined based on the Canadian Constitution and the *Canada Health Act (1984)*
- Federal government provides financial support to provinces and territories for the delivery of primary and supplementary health care services

Health Care Provision in Canada

- 10 provincial and 3 territorial health systems
- Health care (health care services) are provided to all Canadians




Health Care Provision in Canada

- Health expenditures largely paid by the provinces and territories in which an individual resides
- Mixture of public and private care

Health Care Provision in Canada

Total Health Expenditures by Source of Finance



Source: CIHI, National Health Expenditure Trends, 1975-2010

Drug Coverage in Canada

- No universal program for drug coverage
- Mix of private and public coverage
- Each province and territory offers coverage for eligible groups, e.g., income based, high cost drugs, specific conditions

Health Technology Assessment



Health Canada:
Is it safe? Does it work?



**Patented Medicine
Prices Review Board:**
Is the price excessive
compared with some other
developed countries?



CADTH:
How does it compare with
existing treatment options?
Is it good value?



**Federal, provincial, and
territorial public drug plans
and the pan-Canadian
Pharmaceutical Alliance:**
Is it needed? Is it affordable?

CADTH

- An independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence about the optimal use of health technologies (drugs, diagnostics, devices, and procedures).
- Created in 1989, CADTH's products and services are designed to meet a broad spectrum of health care needs.

What We Do

- Generation of evidence and analysis
 - Clinical reviews/critical appraisal of clinical studies
 - Economic evaluations/critical appraisal of manufacture submissions
 - Patient perspective
 - Ethical considerations
- Advice and recommendations

Our Programs and Services



Drug Reimbursement Recommendations

- CADTH Common Drug Review (CDR)
- CADTH pan-Canadian Oncology Drug Review (pCODR)



Health Technology Management Program

- Optimal Use
- Rapid Response
- Environmental Scanning
- Horizon Scanning



Implementation Support and Knowledge Mobilization

- Located in jurisdictions across Canada
- Understand the needs and priorities of local decision-makers
- Offer implementation support and tools to help move evidence into policy and practice



Other Programs and Services

- Scientific Advice

Drug Reimbursement Recommendations

- CADTH Common Drug Review (CDR)
- CADTH pan-Canadian Oncology Drug Review (pCODR)



Our Process

- Different processes depending on the product
- Drug reimbursement recommendations
 - Review initiated by manufacturer
 - Recommendation based on CADTH's assessment of the information provided in the manufacturer's submission dossier
- Other products
 - Based on customer request
 - CADTH conducts research

Drug Reviews — Process

Submission received by manufacturer

CADTH ensures all requirements are met

CADTH conducts:

- Systematic review of clinical information
- Critical appraisal and re-analyses of submitted economic evaluations
- Review of patient input
- Review of additional information as required

Drug Reviews — Process

Information is provided to the expert committee and a recommendation is made

Manufacturer is involved in the process

- Ability to comment on the reports
- Can request reconsideration based on embargoed recommendation

Drug Reviews — How They Are Used

- Participating public drug plans receive the recommendation and evidence reports
- Price is negotiated by the plans
- CADTH provides support to the plans as required (e.g., pricing support tool, clarification)
- Close alignment between CADTH recommendations and public reimbursement decisions

Optimal Use — Process

- Topics for drug and non-drug projects are solicited from customers, including drug plans, ministries of health, and local payers.
- Topics are prioritized by CADTH based on stakeholder interest; number of customers who are requesting
- Multidisciplinary research team is formed

Optimal Use — Process

- Evidence generation/analysis occurs
 - Systematic review of clinical information
 - Generation of economic information
 - Information on ethics, legal, social implications; patient experience; implementation
- Information provided to the expert committee
- Recommendation is made

Optimal Use — How They Are Used

- Recommendations and evidence reports are posted
- Customers will use these documents to make policy and practice decisions and potentially to negotiate prices/costs

Thank You

Stay Connected



requests@cadth.ca

CADTH